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Abstract
Human pluripotent stem cells (hPSCs) were conventionally cultured on feeder cells that
are isolated from mouse embryonic fibroblast (MEF). However, these culture compo‐
nents could contaminate the hPSCs and can limit the application of hPSCs for clinical
use. On the other hand, we demonstrated that exogenous basic fibroblast growth factor
(bFGF) could be omitted from the hPSC culture media if we used the suitable feeder
cells. We also showed that although hPSCs can proliferate on the feeder-free culture
system, however, genetic instability of hPSCs has been reported in such environment.
Feeder cells enable hPSCs to maintain their pluripotency. The feeder cells are usually
grown in a culture medium containing fetal bovine serum (FBS) prior to coculture with
hPSCs. The use of FBS might limit the clinical application of hPSCs. We proposed the
use of human cord blood-derived serum (hUCS) and showed a positive effect on culture
of mesenchymal stem cells. The results showed that human foreskin fibroblasts (HFFs)
cultured  in  hUCS-containing  medium  (HFF-hUCS)  displayed  fibroblastic  features,
short population doubling times, high proliferation rates, and normal karyotypes after
prolonged culture. These studies of hPSC xeno-free culture have been growing in both
basic research and clinical trial. The data regarding the current clinical trials of using
hPSCs convince the researchers not only about the possibility of application of hPSCs
for cell-based therapy, but also the quality of established hPSC lines. Most of the hPSC
lines that were published in the literature and registered in the National Institute of
Health (NIH), hPSCreg of the European Union are not Good Manufacturing Practice
(GMP) grade cell lines. Since one of the goals of using hPSCs is therapeutic purpose,
GMP for derivation, cultivation, and handling the hPSCs are required. This chapter also
reviews the state-of-the-art xeno-free culture system of hPSCs in the respect of future
clinical applications.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
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1. Introduction
The ultimate goal of pluripotent stem cell research is to improve quality of life and patient
treatment. The human pluripotent stem cells (hPSCs) can be classified as human embryonic
stem cells (hESCs) and human-induced pluripotent stem cells (hiPSCs). hESCs can be derived
from the inner cell mass (ICM) of the preimplantation embryos [1]. hiPSCs can be generated by
reprogramming the somatic cells using the exogenous transcriptional factors and resulting in
the pluripotent cells [2]. The successful derivation of hESCs and hiPSCs holds the great hope of
treatment of incurable diseases, and the hPSC-related studies have been growing with regard
to the potential of hPSCs.
hPSCs was firstly cultured in the medium containing the fetal bovine serum (FBS) and
cocultured with mouse embryonic fibroblast (MEF) feeders [1, 2]. However, such conditions
might introduce the contamination of animal pathogens to the hPSCs and make hPSCs
unsuitable for clinical applications. Thus, elimination of all animal products during the
derivation, long-term culture as well as differentiation of hPSCs is necessary prior to applica‐
tion of hPSCs in clinical cell therapy. Because the ultimate aim of pluripotent stem cell research
is to improve quality of life and patient outcome, the more defined culture systems of hPSCs
were progressively developed. The researchers firstly developed xeno-free culture system that
consisted of a growth medium containing Knockout serum replacement (KO-SR) and basic
fibroblast growth factor (bFGF) instead of FBS [3–5]. MEF feeder cells were replaced by the
humanized feeder cells derived from human tissues. Later, the researchers have developed
various xeno-free culture media, and xeno-free extracellular matrices which support the
growth and pluripotency of hPSCs [6–10]. Recently, commercial xeno-free, defined culture
media and extracellular matrix has been developed and available for the researchers.
2. Human pluripotent stem cells properties
hPSCs are widely accepted as the valuable source for cell-based therapy due to their ability of
differentiation toward three embryonic germ layers and process cell division indefinitely [11].
Although the origin of hESCs and hiPSCs is different, they share similarities in the morpho‐
logical appearances and the molecular levels. The unique morphological appearances of hPSCs
can be identified by the tightly pack colonies with defined borders. The clear cytoplasm and
distinctive nuclei of the individual cells can be observed. hPSCs expressed the pluripotent-
related transcriptional factors including OCT-4, Nanog, Sox2, Nodal, hTERT, Rex1 as well as
positive for stage-specific-embryonic antigen (SSEA)-3, SSEA −4, tumor-recognition antigen
(TRA)-1-60 and −1-81, expressed high level of alkaline phosphatase and telomerase activity [1–
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10]. Mellon et al. 12] and Guenther et al. [13] reported that there were no significant gene
expression differences between hESCs and hiPSCs. However, some studies reported the
differences in the methylation profile between hESCs and hiPSCs [14–16]. This can reflect the
genetic and epigenetic abnormalities during the reprogramming process or even the differ‐
ences of cell culture condition in different laboratories [17]. Although the similarities and
differences between hESCs and hiPSCs are contradictory, the researchers around the world
tried to standardize the culture conditions and characterization of hPSCs with the ultimate
goal to achieve the development of the hPSC culture system for the future clinical application
[18, 19].
3. Good Manufacturing Practice for human Pluripotent Stem Cells
Since one of the goals of using hPSCs is therapeutic purpose, Good Manufacturing Practice
(GMP) for derivation, cultivation, and handling the hPSCs are required. Most of the hPSC lines
that were registered in the National Institute of Health (NIH), hPSCreg of the European Union
as well as the data published in the literature are not GMP grade cell lines. Non-GMP grade
cell lines are usually contacts to the animal products especially through the feeder cells, serum,
and extracellular matrix [20, 21]. The researchers found that culture of hESCs on the feeder
cells derived from the mouse embryonic tissues may contaminate nonhuman sialic acid
(Neu5Gc) molecules, which can stimulate the immune rejection after transplantation [22].
Moreover, FBS that was supplemented in the culture medium of feeder cells might contain
bovine pathogens such as bovine spongiform encephalitis (BSE) and limits the use of hPSCs
for clinical applications [23]. Therefore, the materials for hPSC culture system that compliant
for clinical application should be verified that the materials are GMP-grade and animal-free
products. Importantly, the clinical-grade hPSCs should be generated under the ethical
consideration guidelines that strictly followed the national law, from the traceable and healthy
donors and the culture system should follow the standard operating procedures (SOPs) of
GMP.
4. Derivation of human pluripotent stem cells
The recent advances in GMP derivation of hPSC lines are using xeno-free reagents/materials
and replacing the mouse feeders with GMP-qualified human feeders or recombinant human
proteins [24–28]. Regarding the xeno-free hPSC derivation, there are several steps that should
be considered in order to meet the GMP or criteria for clinical grade hPSCs.
For hESC derivation, the zona pellucida of the blastocyst embryos has to be removed prior to
isolation of the ICM. The zona pellucida could be digested by the acid Tyrode’s solution or
pronase [3–5, 29]. To avoid the destructive effect of the acid or enzyme, the laser-assisted zona
pellucida removal and the mechanical cut using surgical blade or needle were successfully
applied [30–32]. Enzymatic removal, laser assisted, and mechanical dissection of zona
pellucida are the xeno-free procedures due to these methods has no contact to the animal
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materials. However, further step for derivation of hESCs is separation of the ICM from the
trophectoderm (TE) which the embryo or ICM might contact to the animal products. Tradi‐
tionally, the TE is separated from the ICM by the procedure called immunosurgery. The
immunosurgery technique involves the selective lyses of the TE but not the ICM, resulting to
the TE-free ICM. The use of anti-human serum combined with complement mediated lysis
using guinea pig serum made the immunosurgery technique unsuitable for derivation of xeno-
free hESCs. Therefore, other means such as microdissection of blastocysts using fine needle,
laser-assisted biopsy, and whole blastocyst culture are the promising techniques for xeno-free
ICM isolation [30–32]. The isolated ICM is subsequently plated and cultured for generation of
hESC lines. The following procedures including culture conditions, cell propagation, and
cryopreservation have to manage under the xeno-free conditions.
For hPSC derivation, the early step for derivation of xeno-free hPSCs is isolation and culture
of the somatic cells prior to reprogramming. The somatic cells should be isolated under the
aseptic condition with the minimal invasive technique. It has been reported that hPSCs can be
generated by using several somatic cell types such as skin fibroblasts, peripheral blood
mononuclear cells and even the cells isolated from urine [2, 33, 34]. Replacement of the animal
products by using human grade or recombinant synthetic products during the isolation and
culture of somatic cells is necessary. For example, human dermal fibroblasts can be isolated
and propagated in the culture medium supplemented with human serum. These fibroblast
cells can multiply under the xeno-free condition and suitable for using as the starting cells for
reprogramming. We proposed the use of human cord blood-derived serum (hUCS) and
showed a positive effect on culture of mesenchymal stem cells. The results showed that human
foreskin fibroblasts (HFFs) cultured in hUCS-containing medium (HFF-hUCS) displayed
fibroblastic features, high proliferation rates, short population doubling times, and normal
karyotypes after prolonged culture. Inactivated HFF-hUCS expressed important genes,
including Activin A, FGF2, and transforming growth factor beta-1 (TGFβ1), which have been
implicated in the maintenance of hPSC pluripotency. Moreover, hPSC lines maintained
pluripotency, differentiation capacities, and karyotypic stability after being cocultured for
extended period with inactivated HFF-hUCS. Therefore, the results demonstrated the benefit
of hUCS for hPSC culture system.
However, one of the bottle-neck of derivation of xeno-free hPSCs is the method for reprog‐
ramming of the somatic cells. Originally, the exogenous genes were delivered to the somatic
cells by means of virus such as lentivirus or retrovirus [2, 35]. Because the integration of
lentiviral- or retroviral genome to the host (somatic cells) genome might occur during the
reprogramming process, thus the hPSCs generated by lentivirus- or retrovirus are not the ideal
hPSCs for the clinical use. The clinical applications will require hiPSCs that are free of
exogenous DNA and that can be manufactured through GMP. Recently, reprogramming by
protein, microRNA, episomal vectors, or Sendai virus, a nonintegrating virus is considered
suitable for delivery of the exogenous genes into the somatic cells [36]. We demonstrated
recently that the transgene-free hPSCs can be generated by the temperature-sensitive strain of
Sendai virus and the viral particles were clearly eliminated from the established hPSCs by the
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heat treatment [37]. Thus, derivation of transgene-free hPSCs is a very important step for
generation of xeno-free hPSCs that match the future clinical applications.
5. Culture of human pluripotent stem cells
The culture conditions that allow hPSCs to maintain their pluripotency is the complex
environment and still under investigation. The researchers proved that the pluripotency of
hPSCs is controlled by the TGF pathway which involves the cooperation of Activin and Nodal
signaling pathway [38]. The pathways that related to the maintenance of the pluripotency of
hPSCs might be provided by the secretion of cytokines, growth factors, extracellular matrix
from the feeder cells, synthetic substrates, or culture medium. The improvement of culture
system is not only necessary for maintenance of hPSC pluripotency but also for large-scale
propagation of hPSCs prior to cell transplantation. The aims of our study were to determine
(i) the effect of exogenous bFGF supplementation in the hPSC culture media on the morphol‐
ogy and gene expression of inactivated human cesarean scar fibroblasts (HSFs) and (ii) the
feasibility of using the inactivated HSFs as the feeder cells for culturing the hPSCs. Our results
showed that the cells shrunk and an increase in gap between the cells were observed in the
inactivated HSFs that were cultured in 4 and 8 ng/ml but not in 0 ng/ml bFGF. Expression of
Activin A, bFGF, TGF-β, and BMP4 was similar between inactivated HSFs cultured in 0, 4, and
8 ng/ml bFGF. After two hPSC lines including hESC line (Chula2.hES) and hiPSC line (PFX12)
were cocultured with three conditions of inactivated HSFs for more than ten passages, the
hPSCs lines were subjected to characterization. The results showed that the hESCs and hiPSCs
cultured in 0, 4, and 8 ng/ml bFGF could maintain their undifferentiation state, differentiate
in vitro into three embryonic germ layers, and maintain their normal karyotype. In conclusion,
exogenous bFGF supplementation in the culture medium can be omitted when using HSFs as
the feeder cells for culturing the hPSCs.
5.1. Feeder-dependent culture system
Feeder-dependent culture system referred to the culture system that the hPSCs grown by the
support of feeder cells. The feeder-dependent culture system is the traditional system that was
developed for generation and propagation of hPSCs [1–6]. Feeder cells secreted cytokines,
extracellular matrices and provided the niches that support the growth and maintenance of
pluripotency of hPSCs. Generally, MEFs are used as the feeder for culture of hPSCs. Due to,
MEFs might stimulate the immune response of the patients after transplantation of hPSCs [22].
Therefore, the feeder cells that isolated from human tissues are the better choice for culture of
the clinical-grade hPSCs. Several studies demonstrated that the supportive feeder cells of
hPSCs could be derived from the human tissues. Hovatta et al. [3] firstly demonstrated that
HFFs supported the derivation and culture of hESCs. HFFs supported the pluripotency of
hPSCs by expression of the key genes such as TFG, FGF2, and Activin A which have been
implicated in the maintenance of hPSC pluripotency [39]. Ma et al. [40], the HFFs produced
interleukin-6 and can be used for coculture with mouse embryonic stem cells. However, not
all the HFF lines exhibited the characteristics of supportive feeder cells. The data confirmed
that the foreskin fibroblasts from the different donor secreted different amount of growth
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factors, cytokines, and specific genes related to pluripotency [39, 41]. Therefore, it is necessary
to explore the new supportive feeder cell types in order to develop the xeno-free feeder
dependent culture system of hPSCs. Up to date, feeder cells derived from other sources of
human tissues, for example, human adult fallopian tubal fibroblasts, human fetal skin, human
adult skin, human fetal muscle, human adult muscle, human adult marrow cells, human
umbilical cord mesenchymal stem cells, human amniotic epithelial cells, and human iPS cell
derived fibroblast-like cells had been reported as the supportive feeder cells for culture of the
hPSCs [42–45]. In addition, genetic modification of human feeder cells such as immortal HFFs
or bFGF-secreting HFFs has been developed and proved to be useful for culture of hPSCs [46,
47]. Although replacement of MEFs by human feeder cells can reduce the risk of contamination
of mouse pathogens to the hPSCs, the use of FBS in the feeder cell culture medium does not
meet the xeno-free condition of hPSCs. We recently demonstrated that HFFs cultured in the
medium containing human umbilical cord blood serum (hUCBS) retain their supportive feeder
characteristics for maintenance of hPSC lines [48]. In addition, we used hUCBS for isolation
and culture of cesarean scar-derived fibroblasts (Figure 1). The xeno-free fibroblasts will be
used for the feeder cells and the starting cells for generation of transgene-free hPSCs.
Figure 1. Isolation of fibroblast cells from human cesarean scar tissue. Fibroblast cells grew out from the tissue after
culture for 7 days in the culture medium containing human umbilical cord blood serum (hUCBS). Scale bar = 100 μm.
To generate the clinical-grade human feeder cells, the cells should be derived under the culture
system containing humanized or recombinant GMP materials and reagents. Interestingly,
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Prathalingam et al. [27] demonstrated that the clinical-grade feeder cells can be derived and
cultured in the medium containing the FBS that was derived under the GMP condition. Prior
to use of the feeder cells for derivation of the new hPSC lines or routinely coculture with the
existing hPSC lines, the clinical-grade human feeder cells should be tested for the potential of
the cells to support the proliferation of hPSCs. Although the standard protocol for character‐
ization of the feeder cells is lacking, several methods have been adopted. Inactivation of feeder
cells by irradiation or Mitomycin C treatment is the method for inactivation of feeder cell
proliferation prior to use for coculture with hPSCs. After being inactivated, the feeder cells
should be able to secrete the enough amounts of cytokines and growth factors into the culture
medium. Moreover, the extracellular matrices provided by the feeder play important roles for
maintenance of the pluripotency of hPSCs [7]. The cells that easy to apoptosis after the
inactivation process might probably not be a good supportive feeder cells.
One major concern of feeder-dependent culture system is coating the culture vessel with the
xeno-free matrix in order to enhance the attachment of feeder cells to the surface of the culture
vessel. Typically, porcine-skin-derived gelatin was used for coating the culture vessel prior of
seeding the inactivated feeder cells. To meet the criteria of xeno-free condition, porcine-skin-
derived gelatin should be replaced by recombinant gelatin. Tannenbaum et al. [26] developed
the platform of derivation of xeno-free and GMP-grade hESCs by using recombinant gelatin
and they found no adverse effect of recombinant gelatin on the pluripotency of hESCs. In
addition, Ding et al. [49] showed that human cord blood serum can be used for coating the
culture vessels instead of the porcine-skin-derived gelatin for derivation and maintenance of
hPSCs.
5.2. Feeder-free culture system
It has been proposed that coculture of hPSCs with the feeder layer might contaminate the
harmful substance and cause the risk of graft rejection, viral or bacterial infection, or zoonoses
[50]. To culture hPSCs under the feeder-free condition, several media formulations have been
developed that eliminate the use of fetal bovine serum and reduce or eliminate all animal-
derived components. Therefore, development of feeder-free and xeno-free culture system for
hPSCs by the use of xeno-free reagents and matrices in every cell-handling process is important
for obtaining clinical-grade hPSCs.
Feeder-free culture system is applied for culturing hPSCs without the feeder layers but the
matrices such as Matrigel or recombinant human proteins, together with the commercially
defined hPSC culture medium [51, 52]. Although the genetic and epigenetic instability could
be detected in hPSCs grown under feeder-free condition [53–55], the feeder-free condition
together with defined culture medium is still important because it allows the hPSCs to
proliferate robustly.
In order to propagate and maintain the pluripotency of hPSCs under the feeder-free condition,
it is necessary to provide the cell adhesion coating that support the proliferation of hPSCs.
Matrigel, the solubilized basement matrix extracted from mouse Engelbreth-Holm-Swarm
sarcoma is the widely used matrix. The major components of Matrigel include laminin,
collagen IV, heparan sulfate proteoglycan, and entactin. In addition, Matrigel contains growth
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factors such as TGF-beta, fibroblast growth factor, TPA, and insulin-like growth factor [56,
57]. Matrigel provides the complex extracellular matrices that support the cell communication
and the suitable microenvironment for the hPSCs to grow as well as maintain their pluripo‐
tency. Although hPSCs proliferated robustly on Matrigel, the origin of Matrigel makes this
matrix unsuitable for maintaining the clinical-grade hPSCs. Recently, Ding et al. [49] devel‐
oped the humanized ECM by using umbilical cord blood serum (UCBS) as the matrix for
derivation and culture of hPSCs. The best result was obtained when UCBS was used in
combination with the basal medium supplemented with bFGF, fibronectin, and Y-27632. Other
humanized matrices, for example, human placental-derived ECM and H9-hESC embryoid
body–derived ECM have been proved to support the pluripotency of hPSCs [58, 59]. The hPSC
lines cultured with the ECM derived from both types of human tissues or cells in the defined
serum and xeno-free culture media such as TeSR2, sustained their pluripotency after pro‐
longed culture. However, lot-to-lot variations in the individual serum donor or tissue-derived
ECM can affect the effectiveness of the serum or ECM in maintaining the pluripotent state of
hPSCs. In order to develop the defined-feeder-free cell adhesion coating, individual extracel‐
lular matrix (ECM) proteins have been used instead of Matrigel. Several ECM including
laminin, fibronectin, vitronectin, and collagen support the proliferation of hPSCs. Those ECM
can be used as single or in various combinations. Interestingly, the studies have demonstrated
that recombinant laminin-511 and recombinant vitronectin enable to support the growth and
maintain the pluripotency of hPSCs [60, 61]. To improve feeder-free culture system, cell
adhesion proteins can be added to ECM component. E-cadherin, the cell adhesion protein
improved the attachment and expansion of hPSCs when the cells were cultured in defined
media such as mTeSR1 and xeno-free media, TeSR2 [62]. Moreover, recombinant E-cadherin
fusion protein supported the proliferation of the other pluripotent cells [63]. Additional
developments in defined culture surfaces include synthetic peptide coatings such as Synthe‐
max, Peptide acrylate surfaces (PAS), or synthetic polymers have been proved to support the
growth and pluripotency of hPSCs after prolonged culture [64]. The combination of human
ECM proteins or cell adhesion molecules and synthetic biomaterials with well-designed
surfaces and/or structures in the presence of a chemically defined medium containing
recombinant growth factors would offer a xeno-free alternative to feeder cells for culturing
hPSCs and maintaining their pluripotency. Because the xeno-free and feeder-free culture
system is suitable for generation of hPSCs for clinical application, we reprogrammed CD34+
cells by the temperature-sensitive Sendai viral vectors carries OCT-4, SOX2, KLF4 and c-MYC,
on Pronectin F plus (Sanyo Chemical Industries, Kyoto, Japan) coating matrix and cultured
the cells in ReproFF (ReproCELL, Yokohama, Japan) culture medium (Figure 2). We will use
this newly established hPSCs for further development of xeno-free culture system. In our study
[48], the hPSC lines were derived and cultured on HFF feeder layer. The hPSC lines were
continuously maintained on either mitomycin-C inactivated HFF-FBS or mitomycin-C
inactivated HFF-hUCS in serum-free hPSC culture medium. The serum-free hPSC culture
medium comprising 80% Knockout Dulbecco’s modified Eagles’ medium (KO-DMEM), 20%
KO-SR, 1% nonessential amino acid, 1% Glutamax, 1% penicillin-streptomycin, 0.1 mM β-
mercaptoethanol (all from Invitrogen), and 8 ng/ml bFGF (R&D Systems, Minneapolis, MN,
USA).
Pluripotent Stem Cells - From the Bench to the Clinic148
Figure 2. Human-induced pluripotent stem cell culture on feeder-free condition.The transgene-free human-induced
pluripotent stem cells generated from CD34+ cells and culture in feeder-free culture system. Scale bar = 500 μm.
6. Contamination concern
Prior to clinical application, xeno-free hPSC lines should be tested and evaluated for their
biological safety. The evaluation should follow the guidelines that developed for clinical trials
or therapies. The hPSC lines should be free from serious pathogenic microorganisms such as
human immunodeficiency virus (HIV) and human papilloma virus (HPV). On the other hand,
hPSC lines should also be free from mycoplasma contamination. Although Romorini [65]
demonstrated the successful elimination of the mycoplasma contamination in their newly
established hPSC lines but the mycoplasma-free newly established cell line is the ideal cell line
for therapeutic application. Moreover, the level of endotoxin in the culture medium of hPSCs
should meet the requirement of the national or international standard. Other biological test,
for example, injection of the hiPSCs into the chorioallantoic and yolk sac of the chicken for
testing unknown pathogenic microorganisms can be performed [25].
7. Clinical trial and therapeutic application
The clinical trial and therapeutic application requires hPSCs that were derived, cultured, and
differentiated under the xeno-free and GMP conditions. Despite controversies and difficulties,
the clinical trials using hESCs started in 2010 and continue ongoing. Geron Corporation, the
biotechnology company based in California, USA began a clinical trial in patients with spinal
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cord injuries using hESCs in 2010. The patient was transplanted with oligodendrocyte
precursor cells derived from hESCs. Unfortunately, the project was discontinued a year later
because the company changed their business strategy. There is no official data that has been
published from the study of Geron. However, the project has been started and continued again
by Advance Cell Technology, the biotechnology company based in Massachusetts. The
company just recently published their preclinical safety data [66]. In 2012, the clinical trials
using hESC-derivative cells were initiated and conducted in the USA. Advance Cell Technol‐
ogy, performed the clinical trials in the patients with Stargardt’s macular degeneration and
age-related dry macular degeneration, which caused the loss of photoreceptor and results in
blindness. Retinal-pigmented epithelial (RPE) cells derived from hESCs were transplanted to
replace the degenerated cells. Interestingly, the visual improvement of the patients had been
preliminarily reported [67, 68]. ViaCyte, the company based in California, USA reported the
successful surgical transplantation of pancreatic precursor cells derived from hESCs for
treatment of Type I diabetes [69]. Recently, the Japanese researchers from RIKEN institute
performed the first clinical trial using hiPSC-derived cells for treatment of age-related macular
degeneration. Autologous hPSCs were differentiated to retinal-pigmented epithelial (RPE)
sheet and later transplanted to the patient. However, the second trial was cancelled due to the
occurring of genetic instability of the cells prior to transplantation [70]. Besides the clinical
trials mentioned above, the hPSC-based products for the treatment of Parkinson’s disease and
others diseases are currently in the pipeline [71].
8. Perspective of collaboration
Although clinically compliant hPSC has been derived, limitations in scale of production and
high costs for culture of hPSCs remain significant challenges. Besides efficiency and safety, the
development of hPSC-based cell therapies are expected to be expensive, time consuming and
might face the clinical failure. Therefore, the collaboration between academy, SME and large
pharmaceutical company can take the advantage of opportunities to tap into various sources
of support. Funding for basic research carried out in the academic setting is available from
national research grant agencies and institutes. In the private sector, SMEs have the possibility
to attract venture capital to fund efforts in regenerative medicine. In addition, the pharma‐
ceutical companies have the possibility to directly support the project using their internal
resources. Besides individually applying for grants or securing other type of funding, the
partners can also join together and obtain consortium grants or support based on collaborative
networks from international initiatives such as the Framework Programs funded by the
European Union. We had developed the similar model by carried out the project with the two
European partners, The University of Copenhagen, Denmark and BioTalentum, Ltd, Hungary.
The project was funded by the European Union under the Framework 7 through the Marie
Curies Actions. The results of the project were not only the publications [72] but also trans‐
ferring the researchers and knowledge between the academy and industry. We believed that
having research partners cover both non-profit and for-profit organizations is of great
advantage when developing hPSC-based cell therapy.
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9. Conclusion
To enable a xeno-free culture system capable of clinical use, it is important to examine the
sources of components used in hPSC derivation, culture, including the reagents used for
handling cells during passaging and the reagents used for cryopreservation. The sufficient
protocols and documentations, development of hPSC derivation and culture conditions under
the strict cleanroom and the use of GMP-grade reagents and materials should be prepared. In
addition to the technical issues involved, establishment of the donor consent documentation
appropriately and utilize forms that specifically states that the cells will be used for cell therapy
purposes have to be prepared. The clinical grade hPSC lines that derived completely under
the GMP conditions will be a valuable source for the future clinical therapies.
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